Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Nick Pizzie acquired 1,920 shares of the stock in a transaction dated Tuesday, June 11th. The shares were bought at an average cost of $20.80 per share, for a total transaction of $39,936.00. Following the completion of the transaction, the chief financial officer now owns 1,920 shares in the company, valued at $39,936. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Nick Pizzie also recently made the following trade(s):
- On Tuesday, March 19th, Nick Pizzie acquired 5,400 shares of Axsome Therapeutics stock. The shares were bought at an average cost of $12.58 per share, for a total transaction of $67,932.00.
AXSM traded down $0.22 on Friday, hitting $22.73. 9,289 shares of the company’s stock traded hands, compared to its average volume of 1,256,763. The company has a market capitalization of $762.47 million, a PE ratio of -19.93 and a beta of 2.78. Axsome Therapeutics Inc has a one year low of $1.94 and a one year high of $26.45. The company has a current ratio of 5.68, a quick ratio of 5.68 and a debt-to-equity ratio of 1.08.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Alethea Capital Management LLC raised its stake in Axsome Therapeutics by 25.5% during the 1st quarter. Alethea Capital Management LLC now owns 1,140,394 shares of the company’s stock valued at $16,228,000 after purchasing an additional 231,965 shares during the period. BlackRock Inc. raised its stake in Axsome Therapeutics by 626.9% during the 1st quarter. BlackRock Inc. now owns 465,587 shares of the company’s stock valued at $6,625,000 after purchasing an additional 401,538 shares during the period. Millennium Management LLC bought a new stake in Axsome Therapeutics during the 4th quarter valued at approximately $871,000. Laurion Capital Management LP bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $3,116,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $1,771,000. 44.22% of the stock is currently owned by institutional investors.
AXSM has been the topic of a number of analyst reports. Cantor Fitzgerald lifted their price objective on Axsome Therapeutics from $16.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. BidaskClub cut Axsome Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, March 3rd. SunTrust Banks initiated coverage on Axsome Therapeutics in a research report on Tuesday, May 28th. They set a “buy” rating on the stock. HC Wainwright set a $15.00 price objective on Axsome Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 5th. Finally, Svb Leerink initiated coverage on Axsome Therapeutics in a research report on Monday, April 8th. They set an “outperform” rating and a $25.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $30.83.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2019/06/14/nick-pizzie-purchases-1920-shares-of-axsome-therapeutics-inc-nasdaqaxsm-stock.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Read More: What is a Special Dividend?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.